RainDance Technologies and Ambry Genetics Launch Industry’s Most Comprehensive DNA Sequencing Panel for ADME Research
Published: Oct 24, 2011
LEXINGTON, Mass. & ALISO VIEJO, Calif.--(BUSINESS WIRE)--RainDance Technologies, Inc., the Digital Biology™ Company, and Ambry Genetics, today announced the launch of a comprehensive targeted sequencing panel to screen genes involved with drug absorption, distribution, metabolism, and excretion (ADME) research. The ADMESeq™ Research Screening Panel enables researchers to simultaneously interrogate 242 known pharmacogenetic genes using next-generation sequencing (NGS) systems.